Inegy (Simvastatin, Ezetimibe)

Simvastatin blocks HMG‑CoA reductase, the enzyme that drives cholesterol synthesis in the liver, leading to increased LDL‑receptor activity and lower circulating LDL. Ezetimibe inhibits the NPC1L1 transporter in the small intestine, reducing the absorption of dietary and biliary cholesterol. Together they provide complementary reductions in blood cholesterol.

The dose of Inegy is individualized by the prescribing clinician based on the patient’s lipid profile, cardiovascular risk, and tolerance. The prescriber determines the appropriate strength and dosing schedule, which may be adjusted during therapy to achieve target lipid levels.

Safety of Inegy during pregnancy or lactation has not been established. Statins are generally contraindicated in pregnancy because of potential fetal toxicity, and ezetimibe lacks sufficient data. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative lipid‑lowering strategies with their healthcare provider.

To order Inegy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Inegy combines a statin with ezetimibe, offering greater LDL‑cholesterol reduction than a statin alone, especially in patients who do not reach targets with monotherapy. Compared with ezetimibe alone, the addition of simvastatin provides a stronger effect on LDL while maintaining a similar safety profile when used as directed.

Inegy tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat, and direct sunlight to maintain potency. Do not store in bathrooms or near kitchen appliances that generate heat.

Inegy is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water. Consistency in the time of day helps maintain steady drug levels, and patients should follow any specific instructions regarding meals.

The most serious adverse events include rhabdomyolysis (muscle breakdown that can lead to kidney failure), severe liver injury (marked elevation of liver enzymes or jaundice), and life‑threatening allergic reactions such as anaphylaxis. Patients should promptly report unexplained muscle pain, weakness, dark urine, or signs of liver dysfunction.

Inegy is contraindicated in individuals with active liver disease, unexplained persistent elevations of hepatic enzymes, known hypersensitivity to simvastatin, ezetimibe, or any excipients, and in pregnant or nursing women. It should also be avoided in patients taking strong CYP3A4 inhibitors or gemfibrozil due to the high risk of muscle toxicity.